The Full Wiki

More info on Pyrovalerone

Pyrovalerone: Wikis

  
  

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

Pyrovalerone
Systematic (IUPAC) name
1-(4-methylphenyl)-2-(1-pyrrolidinyl)pentan-1-one
Identifiers
CAS number 3563-49-3
ATC code none
PubChem 14373
Chemical data
Formula C 16H23NO 
Mol. mass 245.36 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.  ?
Legal status Schedule V (US)
Routes Oral

Pyrovalerone (Centroton, Thymergix) is a psychoactive drug with stimulant effects via acting as a norepinephrine-dopamine reuptake inhibitor (NDRI), and is used for the clinical treatment of chronic fatigue or lethargy[1] and as an anorectic or appetite suppressant for weight loss purposes. It was developed in the late 1960s and has since been used in France and several other European countries. Though pyrovalerone is still occasionally prescribed, it is used infrequently due to problems with abuse and dependence.[2] Pyrovalerone is a Schedule V controlled substance in the United States (U.S.), and is the only stimulant in that category.[3 ] It is closely related on a structural level to a number of other stimulants, such as methylenedioxypyrovalerone (MDPV, MDPK; "Sonic", "Magic", "Monkey Dust") and prolintane (Promotil, Katovit).

Side effects of pyrovalerone include anorexia or loss of appetite, anxiety, fragmented sleep or insomnia, and trembling, shaking, or muscle tremors. Withdrawal following abuse upon discontinuation often results in depression.[4]

The R-enantiomer of pyrovalerone is devoid of activity.[5]

See also

References

  1. ^ Gardos G, Cole JO. Evaluation of pyrovalerone in chronically fatigued volunteers. Current Therapeutic Research, Clinical and Experimental. 1971 Oct;13(10):631-5.
  2. ^ Deniker P, Loo H, Cuche H, Roux JM. Abuse of pyrovalerone by drug addicts. Annales Medico-Psychologiques (Paris) 1975 Nov;2(4):745-8.
  3. ^ "Schedule V Controlled Substances". http://www.deadiversion.usdoj.gov/schedules/listby_sched/sched5.htm. Retrieved 2008-01-13.  
  4. ^ http://www.biam2.org/www/Etr8623.html
  5. ^ Meltzer PC, Butler D, Deschamps JR, Madras BK. 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32. PMID 16480278







Got something to say? Make a comment.
Your name
Your email address
Message